NASDAQHealth CareMedical DevicesSnapshot 2026-07-23
Reading LIVN? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on steady revenue growth. The current thesis state is intact, supported by strong recent financial results, but there are challenges ahead.
The market seems to have priced in a justified valuation, with LIVN appearing cheap compared to its peers. There is a slight expectations gap, indicating that the market is not overly optimistic about future performance.
Management aims to increase revenue growth to 7-8% for 2026, and recent results show progress towards this goal. However, adjusted free cash flow needs improvement to meet targets, and there is a moderate risk of missing earnings expectations.
The long-term thesis hinges on the performance of sector bellwethers like ABT, SYK, and MDT. If these companies continue to perform well, it could support LIVN's growth. Conversely, if they start to miss earnings, it could negatively impact LIVN's momentum.
In the next 1-3 years, LIVN's performance will depend on its ability to meet growth targets and the overall health of the healthcare sector. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. This improvement is driven by the latest earnings beat, which indicates strong financial performance and supports the overall thesis for LIVN. There are no current threats that weaken this assessment.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: If revenue growth falls below the median, it could signal a slowdown in LivaNova's business. This would be a concern for investors.
Confirms:LivaNova reports revenue growth below the sector median of 1% year over year.
Disproves:LivaNova reports revenue growth above the sector median of 1% year over year.
Why it matters: Meeting or exceeding this growth rate shows LivaNova is on track for its 2026 revenue goals.
Confirms:Q2 revenue grew by 7.0% or more when adjusted for currency changes.
Disproves:Q2 revenue grew less than 6.0% when adjusted for currency changes.
Why it matters: New approvals would strengthen LivaNova's place in the growing sleep apnea market.
Confirms:FDA approves new devices for obstructive sleep apnea.
Disproves:No new FDA approvals for OSA devices in the next quarter.
Why it matters: The Q2 results will show if LivaNova's financial health is improving or not. Investors will look for signs of recovery or continued losses.
Confirms one read:Earnings report shows revenue growth year over year of at least 5%.
Confirms the other:Earnings report shows revenue decline year over year of more than -5%.
Why it matters: Hitting this cash flow target is key for LivaNova's money management plans.
Confirms:Adjusted free cash flow reported within the range of $160 million to $180 million.
Disproves:Adjusted free cash flow reported below $160 million.
Why it matters: Updates on the aura6000 System can show how well it is accepted in the OSA market.
Confirms:There are reports of new hospitals or clinics using the aura6000 System for OSA treatment.
Disproves:No new users reported or there is negative feedback from early users.
Why it matters: Keeping this EPS guidance shows good performance and trust from investors.
Confirms one read:Adjusted EPS guidance confirmed at $4.20 to $4.30 during the next earnings call.
Confirms the other:Adjusted EPS guidance is now below $4.15.
